NasdaqGS - Nasdaq Real Time Price USD

Praxis Precision Medicines, Inc. (PRAX)

38.06

-0.03

(-0.08%)

At close: May 8 at 4:00:00 PM EDT

38.06

0.00

(0.00%)

After hours: May 8 at 4:05:08 PM EDT

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. “We were excited to highlight the significant opportunity in DEEs

GlobeNewswire 3 days ago

PRAX
-0.08%
Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

Praxis Precision Medicines ( NASDAQ:PRAX ) First Quarter 2025 Results Key Financial Results Net loss: US$69.3m (loss...

Simply Wall St. 4 days ago

PRAX
-0.08%
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new n

GlobeNewswire 6 days ago

PRAX
-0.08%
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its

GlobeNewswire 6 days ago

PRAX
-0.08%
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT. The webinar, hosted by the Praxis management team, will focus on the company’

GlobeNewswire 30 days ago

PRAX
-0.08%
Praxis Precision Medicines to Participate in Upcoming April Conferences

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April: Praxis management will be presenting a corporate overview at the 24th Annual Needham Virtual Healthcare C

GlobeNewswire last month

PRAX
-0.08%
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. last month

PRAX
-0.08%
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present data from its four late-stage programs in epilepsy and movement disorders at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place from Apr

GlobeNewswire last month

PRAX
-0.08%
Praxis Precision price target lowered to $85 from $150 at Needham

Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing Ulixa sales from its model after the company disclosed last week that Independent Data Monitoring Committee recommended that its study be stopped for futility, due to the results being unlikely to meet the primary efficacy endpoint, the analyst tells investors in a research note. At this time, the firm is assuming that the probability of success for this

TipRanks 2 months ago

PRAX
-0.08%
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in five upcoming investor conferences: Praxis management will be presenting a corporate overview at the 45th Annual TD Cowen Health Care Conference, takin

GlobeNewswire 2 months ago

PRAX
-0.08%
Top Midday Decliners

Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data

PREMIUM
MT Newswires 2 months ago

PRAX
-0.08%

NTAP

DV
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

PRAX
-0.08%
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), an update on other therapies in development and a financial update. Re

GlobeNewswire 2 months ago

PRAX
-0.08%
Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.

BioPharma Dive 2 months ago

CELG-RT

PRAX
-0.08%

ZVRA
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

IGMS

PRAX
-0.08%
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

PRAX
-0.08%

NTLA
Praxis Precision Medicines to Present at Two February Investor Conferences

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences: Praxis management will be participating in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Confer

GlobeNewswire 3 months ago

PRAX
-0.08%
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025 Enrollment in EMBOLD study of relutrigine cohort 2 is on track; targeting NDA filing in 2026 Vormatrigine ENERGY program advancing with read-outs of RADIANT in first half of 2025 and POWER1

GlobeNewswire 3 months ago

PRAX
-0.08%
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, Janu

GlobeNewswire 3 months ago

PRAX
-0.08%
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025 BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the de

GlobeNewswire 4 months ago

PRAX
-0.08%

Performance Overview

Return	PRAX	S&P 500 (^GSPC)
YTD	-50.55%	-3.70%
1-Year	-25.00%	+9.18%
3-Year	-68.60%	+37.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines to Participate in Upcoming April Conferences

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision price target lowered to $85 from $150 at Needham

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

Top Midday Decliners

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Praxis Precision Medicines to Present at Two February Investor Conferences

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Performance Overview